Challenge in hyponatremic patients – the potential of a laboratory-based decision support system for hyponatremia to improve patient’s safety
Author:
Sicker Tom1, Federbusch Martin1, Eckelt Felix1, Isermann Berend1, Fenske Wiebke2, Fries Charlotte2, Schmidt Maria1, Kaiser Thorsten13
Affiliation:
1. Institute of Laboratory Medicine, Clinical Chemistry, and Molecular Diagnostics, University of Leipzig Medical Center , Leipzig , Germany 2. Department of Endocrinology, Diabetes, and Metabolism , University Hospital Bonn , Bonn , Germany 3. Institute for Laboratory Medicine, Microbiology and Pathobiochemistry, University Hospital Ostwestfalen-Lippe , Lippe , Germany
Abstract
Abstract
Objectives
Hyponatremia is the most frequent electrolyte disorder in hospitalized patients with increased mortality and morbidity. In this study, we evaluated the follow-up diagnostic, the risk of inadequate fast correction and the outcome of patients with profound hyponatremia (pHN), defined as a blood sodium concentration below 120 mmol/L. The aim was to identify a promising approach for a laboratory-based clinical decision support system (CDSS).
Methods
This retrospective study included 378,980 blood sodium measurements of 83,315 cases at a German tertiary care hospital. Hospitalized cases with pHN (n=211) were categorized into two groups by the time needed for a follow-up measurement to be performed (time to control, TTC) as either <12 h (group 1: “TTC≤12 h”, n=118 cases) or >12 h (group 2: “TTC>12 h”, n=93 cases). Length of hospital stay, sodium level at discharge, ward transfers, correction of hyponatremia, and risk of osmotic demyelination syndrome (ODS) due to inadequate fast correction were evaluated with regard to the TTC of sodium blood concentration.
Results
pHN was detected in 1,050 measurements (0.3%) in 211 cases. Cases, in which follow-up diagnostics took longer (TTC>12 h), achieved a significantly lower sodium correction during their hospitalization (11.2 vs. 16.7 mmol/L, p<0.001), were discharged more frequently in hyponatremic states (<135 mmol/L; 58 (62.4%) vs. 43 (36.4%), p<0.001) and at lower sodium blood levels (131.2 vs. 135.0 mmol/L, p<0.001). Furthermore, for these patients there was a trend toward an increased length of hospital stay (13.1 vs. 8.5 days, p=0.089), as well as an increased risk of inadequate fast correction (p<0.001).
Conclusions
Our study shows that less frequent follow-up sodium measurements in pHN are associated with worse outcomes. Patients with a prolonged TTC are at risk of insufficient correction of hyponatremia, reduced sodium values at discharge, and possible overcorrection. Our results suggest that a CDSS that alerts treating physicians when a control time of >12 h is exceeded could improve patient care in the long term. We are initiating a prospective study to investigate the benefits of our self-invented CDSS (www.ampel.care) for patients with pHN.
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,General Medicine
Reference37 articles.
1. Waikar, SS, Mount, DB, Curhan, GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009;122:857–65. https://doi.org/10.1016/j.amjmed.2009.01.027. 2. Upadhyay, A, Jaber, BL, Madias, NE. Incidence and prevalence of hyponatremia. Am J Med 2006;119:(7 Suppl 1)S30–5. https://doi.org/10.1016/j.amjmed.2006.05.005. 3. Donzé, JD, Beeler, PE, Bates, DW. Impact of hyponatremia correction on the risk for 30-day readmission and death in patients with congestive heart failure. Am J Med 2016;129:836–42. https://doi.org/10.1016/j.amjmed.2016.02.036. 4. Corona, G, Giuliani, C, Parenti, G, Colombo, GL, Sforza, A, Maggi, M, et al.. The economic burden of hyponatremia: systematic review and meta-analysis. Am J Med 2016;129:823–35.e4. https://doi.org/10.1016/j.amjmed.2016.03.007. 5. Rossi, J, Bayram, M, Udelson, JE, Lloyd-Jones, D, Adams, KF, Oconnor, CM, et al.. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care 2007;9:82–6. https://doi.org/10.1080/17482940701210179.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|